Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
June 14, 2016 9:07 AM EDT
Piper Jaffray maintained an Overweight rating and $6.00 price target on CareDx, Inc (NASDAQ: CDNA) following the company's presentation of its DART clinical trial. Piper Jaffray would describe DART's first look data as solid with AlloSure a significantly better predictor of kidney health than creatinine.
Analyst William Quirk... More
June 13, 2016 1:01 PM EDT
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 69.6% LOWER; announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO)... More
